Will Acadia’s Top Institutional Shareholders Benefit Greatly From This Approval?
Acadia Pharmaceuticals (NASDAQ:ACAD) shares are soaring over 55 percent for the drug maker, following the announcement that its Parkinson’s disease psychosis drug pimavanserin was granted a fast track to approval from the FDA. Successful Phase III trials last year means the company will not have to engage in confirmatory Phase IIIs, which were scheduled to begin later this month.
These institutional firms indicated owning shares of ACADIA Pharmaceuticals, Inc. (NASDAQ:ACAD) in Q1 2013. They reported owning a total of 300 shares on 03/31/2013. The shares closed at $7.94 on 03/31/2013.
Here are the six largest positions in ACADIA Pharmaceuticals, Inc. at the end of March 31st, 2013.
Baker Bros. Advisors LLC held 15,621,812 shares on 12/31/2012 worth $72,641,427. This brought the portfolio total to 1.9%.
FMR LLC held 9,652,910 shares on 12/31/2012 worth $44,886,032. This brought the portfolio total to 0.01%.
RA Capital Management LLC held 7,327,092 shares on 12/31/2012 worth $34,070,978. This brought the portfolio total to 12.02%.
Visium Asset Management LP held 4,681,603 shares on 12/31/2012 worth $21,769,454. This brought the portfolio total to 0.76%.
Jeffrey R. Jay held 2,351,477 shares on 12/31/2012 worth $10,934,368. This brought the portfolio total to 9.51%.
BVF Inc. held 1,805,870 shares on 12/31/2012 worth $8,397,296. This brought the portfolio total to 1.55%.
Knowing which stocks have institutional support will help improve your investing skills, and teach you how to ride the waves of strong moves. In fact, “S = Support is Provided By Institutional Investors & Company Insiders” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute — click here and get our CHEAT SHEET stock picks now.